Publication | Closed Access

A Multicenter Phase II Study with Triptorelin (Sustained-Release LHRH Agonist) in Advanced or Recurrent Endometrial Carcinoma: A French Anticancer Federation Study

Endocrine-related CancerMedicinePharmacologyGynecologyPharmacotherapyCancer TreatmentOncologyRecurrent Endometrial CarcinomaGynecology OncologyCancer ResearchSustained-release Lhrh Agonist